Fast and hassle-free
This topic is of particular interest to both healthcare professionals and patients, given the increasing use of semaglutide for managing obesity and type 2 diabetes
Therefore, direct protection of cardiovascular system and favorable effects on multiple cardiovascular risk factors (hyperglycemia, blood pressure, dyslipidemia, body weight) observed in patients receiving GLP-1RAs may provide an explanation for the cardiovascular benefits of GLP-1RAs (Fig
Months 23: Sustained Weight Loss and Plateau Awareness Between months 2 and 3, continuous semaglutide therapy produces cumulative weight loss averaging 10 to 15 pounds for many patients, though individual results range widely based on genetics, diet quality, physical activity, and medication adherence
For cancer patients, your PMC provider coordinates with your oncologist
Retatrutide Phase 3 TRIUMPH-4 data (December 2025): 28.7% mean weight loss at 68 weeks with 12 mg